Wahn U, et al. - In this retrospective cohort study, researchers used a German longitudinal prescription database to assess how allergic rhinitis (AR) symptoms and asthma symptoms/onset are affected by 6 allergen immunotherapies [AITs] (native pollen sublingual/subcutaneous immunotherapy(SLIT)/SCIT, 4 allergoid SCITs) vs symptomatic medication use in patients with birch pollen-associated AR and/or asthma in real-world. AIT patients received ≥2 successive seasonal treatment cycles; non-AIT patients had ≥3 AR prescriptions in 3 seasons or previous month. According to findings, the use of birch pollen AIT resulted in remarkable reductions in AR and asthma medication intake (real-world benefits) up to 6 years post-treatment cessation, in addition to significantly decreasing the risk of new-onset asthma medication use on-treatment.